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Purpose: The aim of this study was to examine the effectiveness of a combined cognitive-
behavioral therapy for insomnia (CBT-I) and hypnotherapy for insomnia (HT-I) program for 
insomnia patients with or without additional depression regarding depressive symptoms and 
various sleep parameters.
Patients and methods: A sample of 63 patients suffering from insomnia received a six-
session sleep intervention, which combined cognitive-behavioral and hypnotherapeutical 
elements. Due to violating exclusion criteria, data of 37 patients were analyzed. Ten patients 
had insomnia comorbid with depression, whereas 27 patients had insomnia only. Sleep diaries 
were implemented to measure various sleep parameters, whereas depressive symptomatology 
was assessed with the anxiety and depression scale and Symptom-Checklist-90-R at baseline, 
before and after the intervention, as well as at 3-months follow-up.
Results: Depressive symptoms decreased from pre to post measurement and follow-up for 
patients with insomnia comorbid with depression, whereas scores of patients with only insomnia 
remained relatively on a low level. Both groups showed a significant increase of sleep efficiency 
and a significant decrease of the duration of wake after sleep onset. However, only patients with 
insomnia and depression revealed a significant reduction of sleep-onset latency and a higher level 
of regeneration. Nondepressive insomniacs, on the other hand, showed a significant increase of 
performance from post measurement to follow-up. For both groups, no change over time was found 
for number of wake after sleep onset, total sleep time, mood in the morning and evening.
Conclusion: Combining CBT-I and HT-I is effective in reducing depressive symptoms and 
improving sleep. Therefore, nonresponders to other forms of therapy, eg, pharmacological, 
interpersonal, or cognitive-behavioral therapy, might benefit from the combined CBT-I/HT-I 
intervention.
Keywords: CBT-I, hypnotherapy, insomnia, depression, adults, intervention
Introduction
Research showed that insomnia is a widespread disorder among individuals in industrial 
nations and is associated with various negative consequences, like health problems, 
increase of medication, job problems, accidents, and a decreased level of quality of life.7 
The lifetime prevalence of insomnia is estimated at 24.6%, and ~40% develop a more 
chronic form of insomnia.6,8 While 2.3% of the people aged 20 suffer from insomnia, 
this number increased to 13.9% at age 35, and dropped again to 5.5% at age 41.8
Due to the close bidirectional relationship between insomnia and affective disorders, 
it is not surprising that in 40% of the cases comorbidities with insomnia occurred 
regularly.13,22 Especially, an association between insomnia and affective disorders was 
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confirmed in various samples.13 Up to 50% of patients with 
insomnia developed a major depressive disorder.8,25 Even 
after controlling for other symptoms, the odds ratio for a 
major depression associated with insomnia is 2.1.6 Hereby, no 
age effects could be detected.2 Conclusively, insomnia is one 
of the most important risk factors for developing a depression 
and prevents remission.12,16 Qualitative predictors for recur-
rence of depression are subjective sleep disturbances and 
anxiety, though higher levels of sleep disturbances occurred 
several weeks prior to recurrence.34,36
Vice versa, 90% of depressive patients reported com-
plaints about their sleep quality and two-thirds of them will 
meet the criteria for insomnia.16,25 Patients with affective 
disorders showed an increased level of sleep-onset latency 
(SOL) and percentage of rapid eye movement (REM) sleep, 
whereas total sleep time (TST), sleep efficiency (SE), slow 
wave sleep (SWS), and REM latency decreased.41 Luik et al, 
however, found that longer REM sleep latency and higher 
REM density were associated with depressive symptoms.28 
Yet, after excluding patients using medication, only REM 
density remained related to depressive symptoms.28
cognitive-Behavioral Therapy for 
insomnia (cBT-i)
Cognitive-behavioral therapy became a standard treatment for 
primary insomnia, as well as insomnia comorbid with medi-
cal or psychiatric disorders.37,38,40 Several studies showed that 
CBT-I influenced various subjective sleep parameters.19,24,29,44 
After CBT-I intervention, often SOL, wake after sleep onset 
(WASO), insomnia severity, and use of sleep medication 
declined, whereas SE, TST, and sleep quality increased. 
Effect sizes fluctuated from small (TST) to large effects (sleep 
quality) depending on the sleep variable and measurement 
method.24 However, younger adults and patients with higher 
values of sleep self-efficacy showed the greatest improve-
ment of SE at post measurement and follow-up.27 Besides 
improving sleep after using a CBT-I intervention, Trauer 
et al reported improved sleepiness, self-efficacy, motoric 
vigilance, health status, beliefs and attitudes about sleep, and 
daytime functioning.44 These improvements are independent 
of age, gender, type, or duration of complaints.46
Comparing regular CBT-I with other forms of therapy, 
eg, pharmacotherapy, relaxation training, and sleep hygiene 
education, showed that CBT-I was superior.1,3,33,35,43 A 
meta-analysis by Okajima et al reported that CBT-I was 
more effective than a control group regarding SOL, WASO, 
time in bed (TIB), and SE.35 Effect sizes ranged from small 
to medium for post measurement and from medium to 
large for follow-up. Differences between subjective and 
objective measurements were found for SOL and TST, which 
only improved in the sleep diaries. A level of good sleep at 
follow-up was achieved by 38% in the CBT-I group, whereas 
none achieved a good level of sleep in the control group.47 
Ashworth et al reported a rate of 67% for clinical remis-
sion of insomnia (vs 11% for self-help CBT-I), and 78% 
for those with additional comorbid depression (vs 17% for 
self-help CBT-I).1 Furthermore, patients with insomnia and 
comorbid diseases reported the poorest sleep hygiene practice 
compared to a group of insomnia only patients, and to good 
sleepers, who reported the best sleep hygiene.45 Comparing a 
CBT-I intervention with a sleep hygiene education revealed 
a reduction of SOL and WASO, as well as an improvement 
of SE for the CBT-I group.14 The same effects account for 
a relaxation training, whereby sleep quality, early morning 
awakening, and TST were equal for both groups.33 Never-
theless, effectiveness of a CBT-I intervention was mediated 
by the change of depression severity, as well as the content 
of the intervention rather than the comorbidity.1,14 Finally, 
adding CBT-I to a treatment, as usual, leads to higher quality-
adjusted life years without a significant increase in cost.48
Focusing on insomnia treatments for depressive patients 
seems to be highly relevant due to the high comorbidity of 
insomnia with depression and their negative influence on 
affective symptoms. Koffel et al reported reduced scores 
for depression from pre to post treatment and to follow-up.24 
In addition, normalized depressive symptoms were shown 
in 87.5% of treatment completers and normalized sleep pat-
terns in 100% of patients with insomnia and depression.42 
Furthermore, SOL and WASO decreased, while TST, SE, 
and sleep quality increased with medium to large effect 
sizes.5,42 On the other hand, higher scores for depression 
were associated with shorter sleep duration and shorter TIB.18 
Additionally, comorbidity reduced anxiety and depressive 
symptoms in patients of the CBT-I group, though this effect 
could not be found in the only cognitive therapy and the only 
behavioral therapy groups.4
The higher reduction of insomnia symptoms, when using 
an insomnia treatment instead of a treatment for depression, 
has proved that insomnia is not just a symptom of depression, 
but rather needs separate treatment.5 Blom et al compared 
patients with insomnia and depression receiving either an 
insomnia (CBT-I) or depression intervention.5 Patients from 
the CBT-I group showed a distinctive increase of SE and 
decrease of SOL and use of sleep medication with medium 
to large effects. Depressive symptoms were unaffected by 
the type of intervention.
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hypnotherapy for insomnia
Adding hypnotherapeutical elements to a CBT-I program 
might improve sleep parameters even more, because insom-
niacs often respond to this kind of therapy and relaxation.32 
A meta-analysis by Lam et al found that hypnotherapy 
increased various subjective sleep parameters from baseline 
to posttreatment.26 In comparison to a waitlist-control group, 
participants receiving hypnotherapy showed decreased SOL. 
However, the number of nighttime awakenings did not differ 
between those two groups. Additionally, a hypnotic sugges-
tion led to an extension of SWS in 81% of young females and 
57% of older females compared with a control group.9,10 This 
enhanced activity led to a better prefrontal cognitive function-
ing. However, this effect was significant only for high and 
middle suggestible participants.10 Besides improving sleep, 
Holdevici et al investigated the effect of an intervention, 
which was based on hypnosis and relaxation, on depressive 
and anxiety symptoms.21 Both men and women showed a 
significant reduction of symptoms for anxiety and depression 
immediately after the intervention and at a 3-months follow-
up.21 Thereby, hypnotherapy seems to be more effective 
than waitlist-control groups, cerebral electrotherapy, and 
pharmacological therapy in improving sleep and reducing 
depressive symptoms.26
research question
The aim of this study was to examine the effectiveness 
of a combined cognitive-behavioral and hypnotherapeuti-
cal program for depressive and nondepressive patients. 
We assumed that patients suffering from insomnia with-
out depression report less sleep problems after 3-months 
follow-up to a sleep intervention than patients suffering from 
insomnia with depression. Furthermore, we assumed that 
depressive symptoms will decrease for both groups, however, 
more predominantly in the group of depressive patients.
Patients and methods
Procedure and sample
This longitudinal pilot study included 74 participants between 
the age of 18 and 65 years suffering from insomnia: difficulties 
falling or staying asleep for at least 1 month. Patients were 
informed via our webpage of the outpatient clinic, newspaper, 
and information sheets in care practices. Prior to participa-
tion, information about diagnostic procedure, post-diagnostic 
measurement, and treatment content was given. Furthermore, 
they were informed that they could quit at any time without any 
negative consequences. After information about procedure and 
treatment, participants gave their written informed consent. In 
a further step, participants completed questionnaires regarding 
their demographic background, current life style, medication, 
sleep problems, as well as somatic and psychological impair-
ments; selected participants were assessed 8 weeks prior to 
the treatment (baseline, t0). This assessment included a sleep 
log for 14 days and further questionnaires for mental health. 
To evaluate effects of waiting time, another assessment with 
the same instruments was conducted right before the 6-week 
intervention (t1) and after the intervention (t2), and at 3-months 
follow-up (t3). This six-session sleep intervention combined 
cognitive-behavioral (CBT-I), eg, psychoeducation, progressive 
muscle relaxation, stress management, and problem-solving, 
and hypnotherapeutical elements for insomnia (HT-I) in the 
form of different trances for each session. Each group session 
lasted for 120 minutes and consisted of four to seven patients 
and two to three trainers in a face-to-face setting. Exclusion 
criteria for data analysis were additional psychotherapy at the 
same time (n=11) leading to a participating sample of 63 adults. 
Furthermore, data sets with .30% of missing data on the post 
measurement (n=26) were excluded from analysis. Thus, 37 
participants with a mean age of 43.86 (SD=13.08; 25 females, 
12 males) were included for statistical analyses. Table 1 shows 
sample description at baseline. The study was approved by the 
ethical board of the University of Tuebingen and carried out 
in accordance with national law and the Helsinki Declaration 
of 1975 (in its current, revised form).
Table 1 sample description at baseline
Variable M (SD) Min Max
age (years) 43.86 (13.08) 21 65
Duration of sleep problems (years) 9.47 (9.69) 0.5 41
Variable Number Percent
gender
Male 12 32.4
Female 25 67.6
Medication
Yes 19 51.4
No 18 48.6
Type of medication
homeopathic 2 10.5
antidepressant 7 36.8
Others 10 52.6
Depression
Yes 10 27.0
No 27 73.0
severity of depression
Normal 18 48.6
Mild 9 24.3
Moderate 2 5.4
severe 8 21.6
Note: n=37.
Abbreviation: M, mean.
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instruments
sleep log
Sleep logs are an essential tool in the assessment of sleep 
problems and sleep disorders. Based on the sleep logs of 
the German association for sleep medicine, each sleep 
log assesses participants’ bedtime, wake-up time, SOL, 
subjective regeneration, daytime functioning, performance, 
medication, and substance consumption over a period 
of 2 weeks.11 Participants are asked to complete these 
sleep logs, but only the second week data will be used for 
statistical analysis to avoid bias of adaption and irritation in 
the first week. For statistical analysis, the following sleep 
parameters are used: SOL, number and duration of WASO, 
TST, SE, mood in the morning and evening, performance, 
and regeneration (“How restful/tired do you feel at the 
moment?”). Mood, performance, and regeneration are 
measured on a six-point Likert scale from 1 (“very good”) 
to 6 (“very bad”).
general Depression scale (aDs)
This 20-item self-report instrument gathers information 
about impairment regarding depressive affect, somatic 
complaints, motoric inhibition, and negative thought pat-
terns. Participants rate the frequency of their impairment on 
a four-point scale referring to the last week. It can be used 
for adults between the age of 14 and 80 years in clinical and 
nonclinical samples. Sum score above 23 is an indicator of a 
depressive disorder. With an internal consistency of α=0.89 
and a split-half reliability of r=0.81. This instrument shows 
adequate psychometric properties.20
symptom-checklist-90-r (scl-90-r)
Subjective impairment of somatic and psychological 
symptoms was assessed with the SCL-90-R, which gathers 
information retrospectively over a period of 1 week and con-
sists of 90 items, which are rated on a four-point scale from 
“not at all” to “very intense”. Adolescents’ (from the age of 
12) and adults’ psychological distress is classified on nine 
subscales: somatization, obsessive-compulsive, interpersonal 
sensitivity, depression, anxiety, hostility, phobic anxiety, 
paranoid ideation, and psychoticism. Three global indices 
give information about participant’s response: Global Sever-
ity Index, Positive Symptom Distress Index, and Positive 
Symptom Total. Internal consistencies for each subscale 
are between α=0.74 and α=0.97 for clinical and nonclinical 
samples. The instrument has demonstrated acceptable retest 
reliabilities between 0.69 and 0.92.15
Data analysis
Statistical analyses were carried out with IBM SPSS Statistics 
23. The P-value was set to P,0.05. For testing the longi-
tudinal effects of this intervention, analyses of variances 
with repeated measures were used. In case of significance 
of the Mauchly test of sphericity, data were corrected using 
the Greenhouse–Geisser correction. Post hoc analyses of 
significant main and interactions effects included Bonferroni 
corrected pairwise comparisons for normally distributed data 
and Wilcoxon tests for non-normally distributed data. The 
effect size Cohen’s d will be reported for group comparisons 
and partial eta squared (η
p
2) for the analyses of variance. 
An effect size of d=0.2 and η
p
2=0.01 shows a small effect, 
d=0.5 and η
p
2=0.06 a medium effect, and d=0.8 and η
p
2=0.14 
a large effect.
Results
group comparisons at baseline
Analyzing the effect of an intervention in depressive and 
nondepressive patients on various variables required a 
comparison at baseline. Thus, t-tests for independent 
samples were conducted which showed that nondepressive 
patients reported a significant better mood in the morning 
and evening, felt more regenerated, more efficient, and less 
psychologically stressed prior to treatment (Table 2). Age, 
duration of sleep problems, SOL, WASO, TST, and SE did 
not differ significantly between the two groups. However, 
depressive patients exceeded the cutoff scores for SOL 
with 36 minutes (cutoff 30 minutes), duration of WASO of 
38 minutes (cutoff 30 minutes), and TST with 357 minutes 
(cutoff 390 minutes) according to literature.
A chi-squared test showed no significant difference 
between depressive and nondepressive patients regard-
ing gender, χ² (1, N=37)=1.93, P=0.16, and medication, 
χ² (1, N=37)=0.01, P=0.92. Patients who completed did not 
differ regarding age, sleep problems, or depression in com-
parison to those who did not complete (all P.0.05).
sleep parameters
According to our hypothesis, it was assumed that various 
sleep parameters from the sleep diary would improve over 
time for both groups; however, these improvements will 
be less distinctive for insomnia patients with comorbid 
depression.
SOL of depressive patients decreased significantly from 
36 minutes at baseline to 21 minutes at post measurement, 
which is under the clinical cutoff, but increased again to 
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30 minutes at follow-up, whereas no significant change 
occurred for nondepressive patients. No significant inter-
action was found, F (3, 105)=1.818, P=0.168. Also, the 
number of WASO showed no significant main or interaction 
effects for neither depressive nor nondepressive patients. 
On average, patients woke up one to two times per night. 
However, duration of WASO decreased from 33 minutes 
before treatment to 17 minutes at follow-up in nondepres-
sive patients. For depressive patients, this main effect was 
marginally significant with 37 minutes at premeasurement 
to 17 minutes at follow-up, though no significant interaction 
occurred, F (3, 105)=1.112, P=0.336; however, the change 
is clinically significant. SE increased from 76% to 82% 
for nondepressive patients; similarly from 75% to 84% for 
depressive patients. Both groups did not differ regarding SE 
after treatment, F (3, 105)=1.315, P=0.275. Nevertheless, a 
significant increase of SE could be revealed only from pre-
measurement to follow-up in nondepressed, P=0.04.
Regeneration was significantly influenced by the pres-
ence of a depression, meaning that depressive patients 
improved their scores for regeneration from premeasurement 
to follow-up, P=0.008, whereas no change occurred for 
nondepressed insomnia patients. The interaction of time and 
group was marginally significant, F (3, 105)=2.281, P=0.084, 
η
p
2=0.061. Regarding performance, nondepressive patients 
showed a significant improvement over time, especially from 
post measurement to follow-up, P=0.036. However, changes 
over time for depressive patients, and the interaction were 
not significant, F (3, 105)=0.327, P=0.806.
Concerning TST, no significant main or interaction 
effects were found, F (3, 105)=1.312, P=0.275, mood in 
the morning, F (3, 105)=0.377, P=0.77, and in the evening, 
F (3, 105)=0.474, P=0.701, meaning that depressive and 
nondepressive patients remained stable over time and did 
not differ among each other. Table 3 shows the effects over 
time for depressive and nondepressive patients.
Depressiveness
Analyses of variance revealed a significant decrease of depres-
sive symptoms measured with the anxiety and depression scale 
(ADS) for depressive, F (3, 27)=9.063, P,0.001, η
p
2=0.502, 
and nondepressive insomnia patients, F (3, 78)=5.208, 
P=0.002, η
p
2=0.167. The interaction of time and group was 
significant, F (3, 105)=6.183, P=0.001, η
p
2=0.15, which 
indicated a significant difference between depressive and 
nondepressive patients and their depressiveness over time. 
Remarkably, depressive patients reported an ADS mean score 
of 31.30 at baseline and 16.84 at follow-up, which is below 
the cutoff score for indicating a depressive disorder. Post hoc 
analysis showed a significant decrease from baseline to post 
measurement, P=0.028, and follow-up, P=0.003, for depres-
sive patients. For nondepressive patients, only marginally 
significant decreases were revealed between baseline and 
follow-up, P=0.052, and premeasurement to post measure-
ment, P=0.083, and follow-up, P=0.071 (Figure 1).
Severity of depression measured with the SCL-90-R 
showed a main effect of time for depressive, F (3, 27)=5.912, 
P=0.003, η
p
2=0.369, and nondepressive patients, F (3, 
78)=2.428, P=0.072, η
p
2=0.085, as well as a significant inter-
action, F (3, 105)=6.183, P=0.001, η
p
2=0.15. Post hoc analy-
ses revealed a significant decrease of depressive symptoms 
between baseline and follow-up, P=0.029, for depressive and 
Table 2 group comparisons of depressive vs nondepressive participants at baseline
Variable Depressive Nondepressive t(35) P-value Cohen’s d
M (SD) M (SD)
age (years) 41.30 (13.45) 44.81 (13.07) 0.72 0.476 –
Duration of sleep problems (years) 9.75 (9.62) 9.36 (9.89) 0.11 0.916 –
sleep-onset latency 36.33 (20.61) 27.91 (29.19) 0.84 0.409 –
Number of WasO 1.44 (1.20) 1.57 (1.14) 0.30 0.859 –
Duration of WasO 38.36 (53.16) 26.30 (25.93) 1.04 0.359 –
Total sleep time (minutes) 357.17 (81.52) 390.36 (58.36) 1.38 0.177 –
Sleep efficiency 75.09 (16.83) 78.13 (11.30) 0.63 0.530 –
Mood in the morning 3.27 (0.80) 2.70 (0.71) 2.10* 0.042* 0.78
Mood in the evening 3.23 (0.80) 2.53 (0.71) 2.58* 0.014* 0.96
regeneration 3.78 (0.83) 3.06 (0.81) 2.39* 0.021* 0.89
Performance 3.38 (0.97) 2.64 (0.66) 2.66* 0.012* 0.99
Psychological distress (scl-90-r) 69.70 (9.44) 56.76 (9.80) 3.60** 0.001** 1.33
Notes: t = statistics for group comparisons; P = probability, *P,0.05, **P,0.01; cohen’s d = effect size. The significant results are shown in bold.
Abbreviations: M, mean; WasO, wake after sleep onset.
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a marginally significant decrease for nondepressive patients, 
P=0.076 (Figure 2).
Discussion
The main goal of this study was to examine the effects 
of a sleep intervention, which combines CBT-I and HT-I 
techniques, to treat insomnia patients with and without 
depression. Data of 37 patients were implemented for statisti-
cal analyses, in which 10 patients suffered additionally from 
depression. Sleep parameters, depression, and psychological 
distress were assessed at four measurement times: 8 weeks 
before intervention (baseline), right before (premeasurement) 
and after the intervention (post measurement), and 3 months 
later (follow-up).
Patients suffering from insomnia and comorbid depres-
sion responded differently to this intervention regarding 
several sleep parameters than insomnia patients without 
depressive symptoms. Whereas the latter group’s SOL 
remained firm under the clinical cutoff of 30 minutes for 
all four measurement points, depressive patients showed a 
decrease in SOL from baseline to post measurement and a 
slightly elevated score at follow-up. These results are in line 
with previous studies such as Taylor et al and Trauer et al, 
who also reported a reduction in SOL.42,44 Although both 
groups did not significantly differ at baseline, patients with 
insomnia and comorbid depression exceeded the clinical 
cutoff, supposedly due to their comorbidity, which might 
lead to more thoughts that are negative and rumination, 
Table 3 Descriptives and analysis of variance for depressive and nondepressive patients
Parameter Time Depressivea Nondepressiveb
M SD F (3/78) P-value ηp2 M SD F (3/78) P-value ηp2
sleep-onset latency t0
t1
t2
t3
36.33
27.03
20.82
30.29
6.52
2.40
4.14
4.99
3.789 0.022* 0.296 27.91
27.88
29.01
27.69
5.62
5.69
8.72
8.15
0.044 0.945 0.002
Number of WasO t0
t1
t2
t3
1.44
1.26
0.93
0.86
0.38
0.35
0.37
0.37
2.605 0.109 0.224 1.57
1.76
1.48
1.36
0.22
0.29
0.30
0.25
2.142 0.123 0.076
Duration of WasO t0
t1
t2
t3
38.36
37.78
21.31
17.36
16.81
16.52
9.78
8.29
3.593 0.061# 0.285 26.30
33.13
24.33
17.42
5.00
5.13
4.29
3.52
4.221 0.017* 0.140
Total sleep time t0
t1
t2
t3
357.17
377.98
383.59
405.51
25.78
20.22
19.05
15.75
1.610 0.210 0.152 390.36
382.81
391.94
398.32
11.23
12.63
12.55
10.04
0.840 0.476 0.031
Sleep efficiency t0
t1
t2
t3
75.09
75.15
83.01
84.27
5.32
5.34
3.41
2.29
3.987 0.059# 0.307 78.13
76.30
80.02
82.02
2.18
2.34
2.49
2.09
4.153 0.017* 0.138
Mood in the morning t0
t1
t2
t3
3.27
3.20
3.07
2.89
0.25
0.22
0.25
0.26
1.544 0.226 0.146 2.70
2.75
2.67
2.52
0.14
0.14
0.14
0.14
2.021 0.118 0.072
Mood in the evening t0
t1
t2
t3
3.23
3.06
3.07
2.86
0.25
0.25
0.18
0.30
1.689 0.193 0.158 2.53
2.58
2.51
2.41
0.14
0.14
0.16
0.13
0.655 0.583 0.025
regenerationc t0
t1
t2
t3
3.78
3.60
3.34
3.10
0.26
0.23
0.26
0.24
5.043 0.018* 0.375 3.06
3.12
3.00
2.97
0.16
0.15
0.15
0.15
0.542 0.655 0.020
Performancec t0
t1
t2
t3
3.38
3.33
3.29
3.18
0.31
0.15
0.27
0.29
0.345 0.793 0.037 2.64
2.76
2.72
2.45
0.13
0.12
0.13
0.13
2.743 0.049* 0.095
Notes: t0 = Baseline, t1 = premeasurement, t2 = post measurement, t3 = 3-months follow-up; an=10, bn=27; csix-point likert scale 1 =very good to 6 =very bad; #P,0.10, 
*P,0.05. The significant results are shown in bold.
Abbreviations: M, mean; sD, standard deviation; WasO, wake after sleep onset; ηp2, partial squared eta.
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group therapy for adults with insomnia and comorbid depression
as well as a higher presleep arousal.23 In the study by Hsu 
et al, an intervention contributed to the reduction of patients’ 
presleep arousal and an improvement of sleep parameters.23 
Furthermore, anticipation and hope for therapy seemed to 
play a major role for these changes in depressive patients, 
due to a tremendous decline from baseline to pre and post 
measurement.30 Nondepressed patients did not show these 
effects of anticipation; however, a higher level of psycho-
logical distress in the group of depressives might explain the 
clinical difference at baseline. Patients with insomnia and 
depression might be more pleased because of the opportunity 
of a therapy and the attention regarding their impairment.
For both groups, duration of WASO decreased and SE 
increased significantly, which is in line with results of Blom 
et al, Koffel et al, and Trauer et al;5,24,44 SE raised up to .80% 
at posttreatment and follow-up. Even duration of WASO 
decreased by almost 50%, which then influences mood, 
SE, and regeneration. For depressive patients, regeneration 
enhanced significantly from baseline to follow-up, whereas 
this was not found for nondepressives. One explanation can 
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Figure 1 Mean scores of aDs scale for depressive and nondepressive patients over time.
Notes: t0 = Baseline, t1 = premeasurement, t2 = post measurement, t3 = 3-months follow-up; #P,0.10, *P,0.05 **P,0.01.
Abbreviation: aDs, anxiety and depression scale.
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Figure 2 Mean scores of scl-90-r subscale depression for depressive and nondepressive patients over time.
Notes: t0 = Baseline, t1 = premeasurement, t2 = post measurement, t3 = 3-months follow-up; #P,0.10, *P,0.05.
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be the significant difference between these two groups at 
baseline and the comorbidity of insomnia and depression. 
Finally, mood in the morning and evening, as well as TST 
remained stable over time for both groups. Koffel et al found 
elevated TST after treatment, though, only small effects 
were reported.24 For depressive patients, TST increased from 
357 minutes at baseline to 405 minutes at follow-up. Due to the 
high level of variance, this difference was not significant.
Furthermore, depressive symptomatology over time dif-
fered for depressive patients in contrast to the nondepressive 
group. Depressive insomnia patients decreased their ADS 
score from baseline to post and follow-up significantly, 
whereas nondepressed patients showed no such changes. This 
result is in line with results from Bélanger et al, Holdevici, 
and Koffel et al.4,21,24 Importantly, after CBT-I treatment, 
depressive patients scored below the cutoff score, indicating 
no clinical abnormality. This result is very important, mean-
ing that such a sleep intervention reduces sleep parameters 
as well as depressive symptoms in patients suffering from 
both disorders.
limitations
However, several limitations have to be listed. For example, 
the implementation of further insomnia-specific question-
naires as the Insomnia Severity Index would be helpful 
to evaluate more precisely insomnia-specific outcomes. 
Besides, more detailed dropout analysis might enhance the 
quality of the results. However, most participants reported 
at the end of the treatment an enhancement regarding their 
sleep quality and mental health, but not all filled in the full set 
of questionnaires and sleep logs for a further measurement. 
Therefore, future research should add either treatment costs 
or award systems for every completed data set.
Besides, future research could investigate the issue that 
different parts of an intervention have different effects on 
sleep behavior, especially focusing on patients suffering from 
insomnia and comorbidities.31 On the one hand, components 
like stimulus control and sleep deprivation appeared to be 
more effective, whereas sleep hygiene alone showed no effect 
on sleep. Furthermore, the use of cognitive strategies rather 
than focusing on the physiological arousal seemed superior.31 
A meta-analysis by Friedrich and Schlarb about psycho-
logical sleep interventions for college students with sleep 
problems revealed that CBT elements were most effective, 
whereas relaxation, which includes hypnotherapy, showed a 
high level of variance regarding effect sizes.17 Furthermore, 
the course of insomnia and depression might be mediated by 
various other variables, eg, presleep arousal, self-efficacy, 
and sleep-related beliefs.39 Gałuszko-Węgielnik et al reported 
a decrease in psychophysiological arousal after CBT-I, but 
did not investigate the impact of arousal on treatment success 
regarding sleep parameters.19 The level of stress vulnerability, 
though, did not influence this effect.19 All these factors should 
be taken into account in further studies addressing insomnia 
patients with comorbid disorders or symptoms.
Conclusion
An intervention combining CBT-I and HT-I is effective in 
reducing depressive symptoms and improving various sleep 
parameters in adults with insomnia comorbid with depres-
sion, whereas patients with isolated insomnia showed these 
enhancements on less sleep parameters. Therefore, nonre-
sponders to other forms of therapy, eg, pharmacological, 
interpersonal, or cognitive-behavioral therapy, could ben-
efit from a combined therapy including hypnotherapy. The 
additional effect of hypnotherapy itself should be part of 
future research. Mediator variables influencing the course 
of insomnia should be considered.
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